A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study

2005 ◽  
Vol 52 (5) ◽  
pp. 1360-1370 ◽  
Author(s):  
Allen J. Lehman ◽  
John M. Esdaile ◽  
Alice V. Klinkhoff ◽  
Eric Grant ◽  
Avril Fitzgerald ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Multicenter Trial ◽  
Double Blind ◽  
Gold Therapy ◽  
Intramuscular Gold ◽  
Double Observer

scholarly journals Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial§

2013 ◽  
Vol 7 (1) ◽  
pp. 96-100 ◽  
Author(s):  
Herbert L. Kellner ◽  
Chunming Li ◽  
Margaret N. Essex
Keyword(s):  
Rheumatoid Arthritis ◽  
Global Assessment ◽  
Signs And Symptoms ◽  
Similar Efficacy ◽  
Multicenter Trial ◽  
Final Visit ◽  
Double Blind ◽  
Intention To Treat ◽  
Parallel Group ◽  
Gastroduodenal Ulceration

Objective: Compare effectiveness of celecoxib versus diclofenac plus omeprazole in improving arthritis signs and symptoms in patients at high gastrointestinal (GI) risk who were enrolled in the CONDOR (Celecoxib vs Omeprazole and Diclofenac in Patients With Osteoarthritis and Rheumatoid Arthritis) trial. Methods: CONDOR was a 6-month, prospective, double-blind, triple-dummy, parallel-group, randomized, multicenter trial comparing celecoxib 200 mg twice daily versus diclofenac slow release (SR) 75 mg twice daily plus omeprazole 20 mg daily. Patients were Helicobacter pylori negative, had osteoarthritis (OA) or rheumatoid arthritis (RA), were aged ≥60 years, were with or without a history of gastroduodenal ulceration, or were ≥18 years with previous gastroduodenal ulceration. Patients’ Global Assessment of Arthritis was determined at each study visit. Results: A total of 4484 patients were randomized to treatment (2238 celecoxib, 2246 diclofenac SR) and included in the intention-to-treat analyses. Least squares mean (LSM) (standard error [SE]) for Patients’ Global Assessment of Arthritis was 3.219 (0.017) and 3.221 (0.017) at baseline for celecoxib and diclofenac SR (p=0.90). Improvement in both groups was similar in months 2, 4, and 6; at month 1 the LSM (SE) was 2.647 (0.017) and 2.586 (0.017) for celecoxib and diclofenac (p=0.0025). LSM difference (SE) from baseline to final visit demonstrated an improvement of 0.75 (0.02) in celecoxib-treated patients and 0.77 (0.02) in diclofenac SR-treated patients (p=0.42). Conclusions: Celecoxib and diclofenac plus omeprazole were shown to have similar efficacy in patients with OA and/or RA at increased GI risk who were enrolled in the CONDOR trial. Trial Registry: Trial was registered under ClinicalTrials.gov identifier NCT00141102.

Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-cd4 antibody, cm-t412, in rheumatoid arthritis patients receiving concomitant methotrexate

1995 ◽  
Vol 38 (11) ◽  
pp. 1581-1588 ◽  
Author(s):  
Larry W. Moreland ◽  
Parks W. Pratt ◽  
Maureen D. Mayes ◽  
Arnold Postlethwaite ◽  
Michael H. Weisman ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Multicenter Trial ◽  
Double Blind ◽  
Double Blind Placebo

A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritis

1986 ◽  
Vol 5 (1) ◽  
pp. 56-61 ◽  
Author(s):  
H. Van Der Leeden ◽  
B. A. C. Dijkmans ◽  
J. Hermans ◽  
A. Cats
Keyword(s):  
Rheumatoid Arthritis ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Gold Therapy

Oral budenosid is highly effective in the treatment of collagenous colitis: A randomized, double-blind, placebo-controlled, multicenter trial

2001 ◽  
Vol 120 (5) ◽  
pp. A40-A40 ◽  
Author(s):  
S MIEHLKE ◽  
P HEYMER ◽  
T OCHSENKUEHN ◽  
E BAESTLEIN ◽  
G YARIAN ◽  
...  
Keyword(s):  
Collagenous Colitis ◽  
Multicenter Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Highly Effective
Sign in / Sign up

Export Citation Format

Share Document